Abstract

The switch strategy in patients with age-related macular degeneration

Despite the improved diagnosis, age-related macular degeneration (AMD) remains the leading cause of irreversible vision loss in the population aged 50 years or over. Intravitreal anti-VEGF therapy is the first-choice treatment for neovascular AMD. In spite of repeated injections of anti-vascular endothelial growth factor, hardly any improvement of visual acuity or stopping of the disease progression is observed in 25% of the patients. The possible causes of resistance to anti-VEGF therapy continue to be under investigation. A single universal regimen for this patient group has not been developed yet. There have been reports that switching from ranibizumab to bevacizumab or aflibercept could be expected to be more effective with regard to repeated injections (the so-called switch strategy).

Piśmiennictwo

1. Rejdak R.. Biblioteka okulisty praktyka: monografia AMD – diagnostyka i leczenie zwyrodnienia plamki związanego z wiekiem. Via Medica, Gdańsk 2016

2. Nixon DR, Flinn N. Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab. Clin Ophthalm 2017;11:715-21

3. Kaczmarek D, Dembowska M, Pomorska M, Kaczmarek R. Terapia ranibizumabem jako alternatywa u pacjentów objętych Programem Lekowym leczenia wysiękowej postaci zwyrodnienia plamki związanego z wiekiem niereagujących na terapię afliberceptem. Kwartalnik Medyczny Okulistyka – wydanie specjalne maj 2018;21:16-20

4. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 2016;10:1857-67

5. Waize M, Todorova MG, Masyk M, et al. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. BMC Ophthalmol 2017;17(1):79

6. Roberts PK, Zotter S, Montuoro A, et al. Identification and Quantification of the Angiofibrotic Switch in Neovascular AMD. Invest Ophthalmol Vis Sci 2019;60:304-11

7. Wytyczne Polskiego Towarzystwa Okulistycznego dotyczące leczenia wysiękowej postaci zwyrodnienia plamki związanego z wiekiem. www.pto.org.pl. Stan na dzień 26.11.2020

8. Chaili S, Adrean S. A Comparison of Management Strategies and Treatment Results for Neovascular Age-Related Macular Degeneration with a Focus on the Treat-Extend-Stop Protocol. J Eye Dis Disord 2018;3:3

9. Freund KB, Mrejen S, Gallego-Pinazo R. Current Strategies for the Management of Treatment – Resistant Neovascular Age-Related Macular Degeneration. Curr Ophthalmol Rep 2014;2:6-13

10. Ehlken C, Jungmann S, Böhringer D, et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye 2014;28:538-45

11. Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye 2015;29:721-31

Do góry